Abbot Buys Kos For $3.7 Billion

Nov. 6, 2006
Adds cholesterol treatments to product line.

U.S. healthcare group Abbott Laboratories said Nov. 6 it was acquiring Kos Pharmaceuticals Inc. for $3.7 billion to add cholesterol treatments to its business. "Kos Pharmaceuticals is an excellent strategic fit for Abbott, both scientifically and commercially," Abbott chief executive Miles White said.

"This acquisition expands Abbott's presence in the lipid management market and will provide several on-market and late-stage pipeline products," he said.

Kos's two main drugs are Niaspan, a tablet that raises "good" levels of cholesterol, and another cholesterol treatment called Advicor. Such treatments are turning into blockbusters for drug companies as wealthier countries tackle rising levels of obesity.

Abbott is paying $78 per share for Kos, a hefty premium of 56% on the drugmaker's closing price on Nov. 3.

Copyright Agence France-Presse, 2006

Popular Sponsored Recommendations

Service Lifecycle Management – Challenges and Opportunities

Feb. 18, 2024
Gain insights into the next wave of aftermarket optimization with Harvard Business Review’s whitepaper, in association with Tavant. Get an in-depth look at AI-powered Service ...

See how 3M Enabled B2B Buyers with Trustworthy Self-Service Buying Experiences

Sept. 11, 2023
This one-pager explores the importance of enabling B2B buyers with self-service purchasing experiences that engender trust and provides insights into the steps businesses can ...

See how 3M Enabled B2B Buyers with Trustworthy Self-Service Buying Experiences

Sept. 11, 2023
This one-pager explores the importance of enabling B2B buyers with self-service purchasing experiences that engender trust and provides insights into the steps businesses can ...

Unlock Hidden Value in ERCOT: Leveraging Data for Customer Success

March 12, 2024
This webinar is a must-attend event for industry professionals seeking innovative energy management solutions driven by data and AI advancements to unlock hidden value in ERCOT...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!